Navigation Links
Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
Date:6/24/2008

-First A2A Adenosine Receptor Agonist Approved for Use in Identifying

Coronary Artery Disease-

DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability of Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide MPI -- a test that detects and characterizes coronary artery disease -- in patients unable to undergo adequate exercise stress. Lexiscan, co-developed with CV Therapeutics (Nasdaq: CVTX), is the first A2A adenosine receptor agonist shown to be safe and effective as a pharmacologic stress agent in MPI studies. The A2A adenosine receptor subtype is primarily responsible for coronary vasodilation.

"Our clinical experience shows that an increasing number of patients are requiring pharmacologic stress agents for MPI studies," said Gregory Thomas, M.D., Clinical Associate Professor of Medicine and Director of Nuclear Cardiology Education at the University of California at Irvine School of Medicine. "Lexiscan will be an important option in helping to ensure proper diagnosis of coronary artery disease in these patients."

MPI tests, commonly called cardiac stress tests, identify areas of poor blood flow in the heart to determine the extent of coronary artery disease, a condition that affects 16 million Americans and is responsible for more than 450,000 deaths annually in the United States. Many patients exercise on a treadmill to generate the increase in coronary blood flow necessary to perform an MPI study. However, almost half of patients undergoing cardiac stress tests each year are unable to exercise adequately because of medical conditions. For these patients, a ph
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
4. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
5. Pharsight Launches PK Accelerator(TM)
6. IS Clinical Launches New ADVANCE+ Skincare Line
7. EH&E Launches Interactive Discussion Forum for Healthcare Environment of Care Professionals
8. BioSpace Launches EuroBio(TM) Online Community
9. NanoInterventions Launches New, Rapid Testing System for Coronary Stents
10. Thomson Reuters Launches New Biomarkers Solution
11. Cardiac Science Launches Anywhere Data Management for HIS and EMR Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... American Process Inc. (Atlanta, GA) ... partnership with researchers at Georgia Institute of Technology, ... the USDA’s Forest Products Laboratory to develop ultra-strong, ... is a rapidly emerging high performance nanomaterial extracted ... to replace heavy steel structures within cars, such ...
(Date:11/18/2014)... November 18, 2014 2014 ... Industry is professional and in-depth report on ... basic information, including its definition, characterization, application, ... outline. This exploration covers the worldwide business ... industry examination covering macroeconomic environment & financial ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... Jan. 28, 2011 Neuralstem, Inc. (Amex: ... with ReNeuron, Ltd. ending litigation between the parties.  The ... against ReNeuron in Neuralstem, Inc. v. ReNeuron, Ltd. ... pending in the United States District Court for the ...
... WASHINGTON, Jan. 27, 2011 Following are the comments ... (D-Ore.) on USDA,s announcement Thursday that the agency will ... engineered (GE) alfalfa, a key commodity in dairy farming, ... GE crop approved for widespread planting. Leahy and DeFazio ...
... Scientists have created a diamond-like lattice composed of gold ... place by strands of DNA. The structure a ... pieces known as capsids, linked by the very stuff ... scientists, ability to combine an assortment of materials to ...
Cached Biology Technology:Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd. 2USDA's Decision Thursday on Genetically Engineered Alfalfa -- Leahy and DeFazio Warn About USDA Decision Lifting All Protections for Organic and Conventional Farmers 2A mix of tiny gold and viral particles -- and the DNA ties that bind them 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... and the debriefing today, the Russian State Commission has given ... CEST. Today,s go-ahead marks the last milestone along the ... tiny variations in the thickness of ice floating in the ... land, the mission will provide scientists with hard evidence on ...
... of Pittsburgh provides the first identification of a human ... in products from electronics to plasticsand in laboratory tests ... to the tiny components, according to findings published online ... open the door to the use of carbon nanotubes ...
... After years of preparation and anticipation, scientists who discover ... key question about Alzheimer,s disease: Will drugs that block ... called amyloid-beta slow the progression of the devastating disease? ... Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
Cached Biology News:CryoSat-2 ready for launch 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 3
... 100 ml supplied as a 5x ... antibodies from membrane-bound proteins without destroying ... chemiluminescent or radioisotopic signals from blots. ... blots. Supplied as a 5X solution ...
...
... The Helios gene gun optimization kit ... in optimizing parameters affecting particle delivery with ... 0.25 g each of 0.6 micrometer, 1.0 ... included is a cartridge kit, that provides ...
... Tecans fully automated solution for cell ... automation for cell-line maintenance, expansion, harvesting ... system built upon standard, industry proven ... handling configuration capable of both rapid ...
Biology Products: